Skip to main navigation Skip to search Skip to main content

'It's not about money, it's about my health': determinants of participation and adherence among women in an HIV-HSV2 prevention trial in Johannesburg, South Africa

  • Catherine MacPhail
  • , Sinead Delany-Moretlwe
  • , Phillippe Mayaud

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)

Abstract

High levels of adherence in clinical trials are essential for producing accurate intervention efficacy estimates. Adherence to clinical trial products and procedures is dependent on the motivations that drive participants. Data are presented to document reasons for trial participation and adherence to daily aciclovir for HSV-2 and HIV-1 genital shedding suppression among 300 HIV-1/HSV-2 seropositive women in South Africa. In-depth interviews after exit from the trial with 31 randomly selected women stratified by age and time since HIV diagnosis confirmed high levels of adherence measured during the trial. Main reasons for trial participation were related to seeking high-quality health care, which explains high levels of adherence in both study arms. Concerns that women would abuse reimbursements, fabricate data, and share or dump pills were not corroborated. Altruism is not a primary motivator in these settings where access to quality services is an issue. This study provides further evidence that good adherence of daily medication is possible in developing countries, particularly where study activities resonate with participants or fill an unmet need.
Original languageEnglish
Pages (from-to)579-588
JournalPatient Preference and Adherence
Volume6
DOIs
Publication statusPublished - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Primary Health Care
  • Health Promotion

Fingerprint

Dive into the research topics of ''It's not about money, it's about my health': determinants of participation and adherence among women in an HIV-HSV2 prevention trial in Johannesburg, South Africa'. Together they form a unique fingerprint.

Cite this